New data presented by Vertex Pharmaceuticals at European Cystic Fibrosis Society ECFS Conference on Cystic Fibrosis confirms benefits of long-term use of Kaftrio and early treatment with CFTR modulating drugs Five scientific abstracts presented by the company at the ECFS Conference in report this year that KAFTRIO in combination with ivacaftor leads to improved lung function and a reduced risk of lung exacerbations of lung transplantation and death for people with Cystic Fibrosis No loss of lung function was seen at two years for people Patients with CF genotypes FF or F MF treated with KAFTRIO in combination with ivacaftor versus subjects not treated with a CFTR modulator Early age initiation of treatment with KALYDECO ivacaftor preserves lung function Vertex presented the first analysis of data from the Registry of US CF Foundation CFFPR patients of more than people with CF treated with KAFTRIO ivacaftor tezacaftor elexacaftor in combination with ivacaftor for an average of nine months This first interim analysis of an ongoing five-year postauthorisation study abstract WS demonstrated that real world treatment with KAFTRIO in combination with ivacaftor was associated with improved lung function, a reduction in the risk of pulmonary exacerbations from baseline pre-KAFRIO in combination with ivacaftor, as well as a reduction in the risk of lung transplantation and a reduction in the risk of death compared to the historical patient population from the US CF Foundation Registry in No new safety signals identified Vertex also presented data from a long-term real-world study demonstrating how treatment initiation with KALYDECO ivacaftor at an early age preserve lung function to a greater extent than when KALYDECO is started at a later age. abstract WS These results demonstrate the importance of early treatment with this drug for eligible patients